Table II.
Association between Gli2 expression and the clinical and pathological characteristics of patients with EOC.
| Gli2 expression | Nuclear Gli2 expression | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter | n | Positive | Negative | χ2 | P-value | Positive | Negative | χ2 | P-value |
| Age, years | 0.007 | 0.935 | 0.198 | 0.656 | |||||
| <50 | 20 | 11 | 9 | 11 | 9 | ||||
| ≥50 | 41 | 23 | 18 | 25 | 16 | ||||
| Tissue type | 3.684 | 0.298 | 2.443 | 0.486 | |||||
| Serous | 38 | 20 | 18 | 22 | 16 | ||||
| Mucinous | 10 | 4 | 6 | 6 | 4 | ||||
| Endometrioid | 10 | 8 | 2 | 5 | 5 | ||||
| Other | 3 | 2 | 1 | 3 | 0 | ||||
| Stage | 0.856 | 0.355 | 3.457 | 0.063 | |||||
| I–II | 21 | 10 | 11 | 9 | 12 | ||||
| III–IV | 40 | 24 | 16 | 27 | 13 | ||||
| Histological grade | 0.556 | 0.355 | 0.583 | 0.445 | |||||
| G1 | 21 | 10 | 11 | 11 | 10 | ||||
| G2-G3 | 40 | 24 | 16 | 25 | 15 | ||||
| Lymph node metastasis | 0.190 | 0.663 | 0.191 | 0.662 | |||||
| Yes | 23 | 12 | 11 | 14 | 9 | ||||
| No | 38 | 22 | 16 | 22 | 16 | ||||
| Platinum sensitivity | 2.107 | 0.147 | 16.367 | <0.001 | |||||
| Resistant | 17 | 12 | 5 | 17 | 0 | ||||
| Sensitive | 44 | 22 | 22 | 19 | 25 | ||||
Cytoplasmic Gli2 expression is not associated with the investigated clinicopathological characteristics of patients with EOC, while nuclear Gli2 expression is associated with platinum resistance in patients with EOC (χ2=16.367, P<0.001). EOC, epithelial ovarian cancer.